Literature DB >> 22116105

Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study.

C P Geer1, J Simonds, A Anvery, M Y Chen, J H Burdette, M E Zapadka, T L Ellis, S B Tatter, G J Lesser, M D Chan, K P McMullen, A J Johnson.   

Abstract

BACKGROUND AND
PURPOSE: MR perfusion imaging can be used to help predict glial tumor grade and disease progression. Our purpose was to evaluate whether perfusion imaging has a diagnostic or therapeutic impact on clinical management planning in patients with glioma.
MATERIALS AND METHODS: Standard MR imaging protocols were interpreted by a group of 3 NRs in consensus, with each case being interpreted twice: first, including routine sequences; and second, with the addition of perfusion imaging. A multidisciplinary team of treating physicians assessed tumor status and created hypothetical management plans, on the basis of clinical presentation and routine MR imaging and then routine MR imaging plus perfusion MR imaging. Physicians' confidence in the tumor status assessment and management plan was measured by using Likert-type items.
RESULTS: Fifty-nine consecutive subjects with glial tumors were evaluated; 50 had known pathologic diagnoses. NRs and the treatment team agreed on tumor status in 45/50 cases (κ = 0.81). With the addition of perfusion, confidence in status assessment increased in 20 (40%) for NRs and in 28 (56%) for the treatment team. Of the 59 patient-care episodes, the addition of perfusion was associated with a change in management plan in 5 (8.5%) and an increase in the treatment team's confidence in their management plan in 34 (57.6%). NRs and the treatment team found perfusion useful in most episodes of care and wanted perfusion included in future MR images for >80% of these subjects.
CONCLUSIONS: Perfusion imaging appears to have a significant impact on clinical decision-making and subspecialist physicians' confidence in management plans for patients with brain tumor.

Entities:  

Mesh:

Year:  2011        PMID: 22116105      PMCID: PMC7966417          DOI: 10.3174/ajnr.A2811

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  44 in total

1.  QUIPSS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling.

Authors:  W M Luh; E C Wong; P A Bandettini; J S Hyde
Journal:  Magn Reson Med       Date:  1999-06       Impact factor: 4.668

Review 2.  Update on brain tumor imaging: from anatomy to physiology.

Authors:  S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

3.  Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Ramon F Barajas; Jamie S Chang; Mark R Segal; Andrew T Parsa; Michael W McDermott; Mitchel S Berger; Soonmee Cha
Journal:  Radiology       Date:  2009-09-29       Impact factor: 11.105

4.  Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade.

Authors:  Alan Jackson; Andrea Kassner; Deborah Annesley-Williams; Helen Reid; Xiau-Ping Zhu; Kah-Loh Li
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

5.  Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Authors:  L Burt Nabors; Tom Mikkelsen; Steven S Rosenfeld; Fred Hochberg; Narasimha S Akella; Joy D Fisher; Gretchen A Cloud; Yu Zhang; Kathryn Carson; Sabine M Wittemer; A Dimitrios Colevas; Stuart A Grossman
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

8.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

9.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

Review 10.  Arterial spin-labeling in routine clinical practice, part 1: technique and artifacts.

Authors:  A R Deibler; J M Pollock; R A Kraft; H Tan; J H Burdette; J A Maldjian
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-27       Impact factor: 3.825

View more
  19 in total

1.  ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Authors:  K Welker; J Boxerman; A Kalnin; T Kaufmann; M Shiroishi; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

2.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Authors:  Patrick Y Wen; Timothy F Cloughesy; Benjamin M Ellingson; David A Reardon; Howard A Fine; Lauren Abrey; Karla Ballman; Martin Bendszuz; Jan Buckner; Susan M Chang; Michael D Prados; Whitney B Pope; Alma Gregory Sorensen; Martin van den Bent; Wai-Kwan Alfred Yung
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?

Authors:  Michael H Soike; Emory R McTyre; Nameeta Shah; Ralph B Puchalski; Jordan A Holmes; Anna K Paulsson; Lance D Miller; Christina K Cramer; Glenn J Lesser; Roy E Strowd; William H Hinson; Ryan T Mott; Annette J Johnson; Hui-Wen Lo; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Michael D Chan
Journal:  Neuroradiology       Date:  2018-08-10       Impact factor: 2.804

4.  A semi-automated volumetric software for segmentation and perfusion parameter quantification of brain tumors using 320-row multidetector computed tomography: a validation study.

Authors:  Soo Young Chae; Sangil Suh; Inseon Ryoo; Arim Park; Kyoung Jin Noh; Hackjoon Shim; Hae Young Seol
Journal:  Neuroradiology       Date:  2017-03-24       Impact factor: 2.804

5.  How treatment monitoring is influencing treatment decisions in glioblastomas.

Authors:  Martha R Neagu; Raymond Y Huang; David A Reardon; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

6.  Comparison of perfusion- and diffusion-weighted imaging parameters in brain tumor studies processed using different software platforms.

Authors:  Mikhail V Milchenko; Dhanashree Rajderkar; Pamela LaMontagne; Parinaz Massoumzadeh; Ronald Bogdasarian; Gordon Schweitzer; Tammie Benzinger; Dan Marcus; Joshua S Shimony; Sarah Jost Fouke
Journal:  Acad Radiol       Date:  2014-08-01       Impact factor: 3.173

Review 7.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.

Authors:  Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter
Journal:  Expert Rev Mol Diagn       Date:  2014-05       Impact factor: 5.225

8.  Arterial spin labeling: Pathologically proven superiority over conventional MRI for detection of high-grade glioma progression after treatment.

Authors:  Eric Nyberg; Justin Honce; Bette K Kleinschmidt-DeMasters; Brian Shukri; Sarah Kreidler; Lidia Nagae
Journal:  Neuroradiol J       Date:  2016-08-19

9.  The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.

Authors:  Xiang Liu; Rajiv Mangla; Wei Tian; Xing Qiu; Dongmei Li; Kevin A Walter; Sven Ekholm; Mahlon D Johnson
Journal:  J Neurooncol       Date:  2017-09-09       Impact factor: 4.130

10.  Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas.

Authors:  Jerrold L Boxerman; Chad C Quarles; Leland S Hu; Bradley J Erickson; Elizabeth R Gerstner; Marion Smits; Timothy J Kaufmann; Daniel P Barboriak; Raymond H Huang; Wolfgang Wick; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Caroline Chung; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert; Bruce R Rosen; Benjamin M Ellingson; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.